obicetrapib
oral CETP inhibitor Ph. III candidate in cardiology Signif. lipid lowering effect at 5 mg PO QD Nat. Med. NewAmsterdam Pharma B.V., Naarden, NL (Amgen)
Molecules of the Month - August 2022
4 minute read
Sep. 28, 2022
Obicetrapib: an Oral Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor for Dyslipidemia